Innovent Announces Phase 2 study of MazdutideIBI362 in Chinese Participants with Overweight or Obesity Met Primary and All Key Secondary Endpoints
SAN FRANCISCO and SUZHOU, China, June 8, 2022 /PRNewswire/ --Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and other major diseases, announces that the primary and all key secondary endpoints were met in a randomized, double-blind, placebo-controlled phase 2 study of mazdutide (R&D code: IBI362), a glucagon-like...
Source: singaporestar.com